The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR and any relapses occur early

Autoria(s): Ross, Davi D. M.; Grigg, Andrew; Schwarer, Anthony; Arthur, Christopher; Loftus, Kerryn; Mills, Anthony K.; Filshie, Robin; Columbus, Ruth; Reynolds, John; Seymour, John; Branford, Susan; Hughes, Timothy
Data(s)

16/11/2008
Identificador

http://hdl.handle.net/10536/DRO/DU:30060085
Idioma(s)

eng
Publicador

American Society of Hematology
Relação

http://dro.deakin.edu.au/eserv/DU:30060085/reynolds-majoritychronicmyeloid-2008.pdf

http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/1102?maxtoshow=
Palavras-Chave #chronic myeloid leukaemia #patients #imatinib #complete molecular response (CMR) #early relapse
Tipo

Journal Article
Acesso ao item digital